Major Depressive Disorder Clinical Trial
Official title:
Acceptance and Commitment Therapy vs. Cognitive Therapy for the Treatment of Major Depressive Disorder
NCT number | NCT01517503 |
Other study ID # | METC 10/103 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | December 2011 |
Est. completion date | August 2015 |
Verified date | July 2019 |
Source | VU University of Amsterdam |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study will investigate the effectiveness of Cognitive Therapy and Acceptance and Commitment Therapy in a randomized controlled trial among patients with Major Depressive Disorder in routine clinical practice. Furthermore, the study will investigate whether each specific treatment approach is mediated by its proposed theoretical mechanism.
Status | Completed |
Enrollment | 82 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Meeting DSM-IV criteria for MDD 2. Between the ages of 18 and 65-years-old 3. Having sufficient fluency in Dutch to complete treatment and research protocol Exclusion Criteria: 1. DSM-IV criteria for bipolar disorder (past or present) 2. Psychotic disorders 3. Substance dependence disorders (current or within the past 6 months), or 4. Organic brain syndrome. 5. Borderline or antisocial personality disorder |
Country | Name | City | State |
---|---|---|---|
Netherlands | PsyQ | Zaandam |
Lead Sponsor | Collaborator |
---|---|
VU University of Amsterdam |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY (QIDS-SR) | Change from pre-treatment to post-treatment, 6 months follow-up and 12 months follow-up | pre-treatment, post-treatment, 6 and 12 months follow-up | |
Primary | Hamilton Rating Scale for Depression | Change from pre-treatment to post-treatment. | pre-treatment, post-treatment | |
Secondary | Decentering subscale of the Experiences Questionnaire | Change between sessions and to follow-up. | Pre-treatment, in-treatment, and 6 and 12 months follow-up. | |
Secondary | Acceptance and Action Questionnaire | Change between sessions and to follow-up. | Pre-treatment, in-treatment, and 6 and 12 months follow-up. | |
Secondary | Dysfunctional Attitude Scale-revised | Change between sessions to follow-up. | Pre-treatment, in-treatment, and 6 and 12 months follow-up | |
Secondary | Working Alliance Inventory | 3. session | ||
Secondary | Eurohis Quality of Life Scale | Change pre-treatment to post-treatment and to follow-up. | Pre-, post-treatment, 6 and 12 months follow-up | |
Secondary | Relationship Scales | Change pre-treatment to post-treatment and to follow-up. | Pre-, post-treatment, 12 months follow-up | |
Secondary | Implicit Attitude Test | Change pre-treatment to post-treatment | Pre- and posttreatment | |
Secondary | Structured Clinical Interview for DSM-IV (Major Depression Module) | Change in diagnosis of Major Depression Disorder from pre-treatment to post-treatment. | Pre-treatment and post-treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |